nach oben

Erschienen in:

2020 | OriginalPaper | Buchkapitel

3. Pathogenese chronisch-entzündlicher Darmerkrankungen

verfasst von : Britta Siegmund

Erschienen in: Chronisch-entzündliche Darmerkrankungen

Verlag: Springer Berlin Heidelberg

Einloggen, um Zugang zu erhalten

Zusammenfassung

Die Pathogenese der chronisch-entzündlichen Darmerkrankungen ist multifaktoriell und bislang nur unvollständig verstanden. Das vorliegende Kapitel soll dazu dienen, dieses komplexe Netzwerk zwischen Genetik, intestinaler Mikrobiota, intestinaler Barriere sowie dem angeborenen und erworbenen Immunsystem in Bezug auf chronisch-entzündliche Darmerkrankungen darzustellen. Ziel des Kapitels ist es einen Überblick zu geben, für eine tiefere Einsicht wird an mehreren Stellen auf weiterführende Übersichtsartikel verwiesen.

Abreu MT, Fukata M, Arditi M (2005) TLR signaling in the gut in health and disease. J Immunol 174:4453–4460CrossRefPubMed

Antoni L, Nuding S, Wehkamp J et al (2014) Intestinal barrier in inflammatory bowel disease. World J Gastroenterol 20:1165–1179. https://doi.org/10.3748/wjg.v20.i5.1165CrossRefPubMedPubMedCentral

Asseman C, Mauze S, Leach MW et al (1999) An essential role for interleukin 10 in the function of regulatory T cells that inhibit intestinal inflammation. J Exp Med 190:995–1004CrossRefPubMedPubMedCentral

Barrett JC, Hansoul S, Nicolae DL et al (2008) Genome-wide association defines more than 30 distinct susceptibility loci for Crohn’s disease. Nat Genet 40:955–962. https://doi.org/10.1038/ng.175CrossRefPubMedPubMedCentral

Barrett JC, Clayton DG, Concannon P et al (2009) Genome-wide association study and meta-analysis find that over 40 loci affect risk of type 1 diabetes. Nat Genet 41:703–707. https://doi.org/10.1038/ng.381CrossRefPubMedPubMedCentral

Batra A, Pietsch J, Fedke I et al (2007) Leptin-dependent toll-like receptor expression and responsiveness in preadipocytes and adipocytes. Am J Pathol 170:1931–1941. https://doi.org/10.2353/ajpath.2007.060699CrossRefPubMedPubMedCentral

Baud O, Goulet O, Canioni D et al (2001) Treatment of the immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) by allogeneic bone marrow transplantation. N Engl J Med 344:1758–1762. https://doi.org/10.1056/NEJM200106073442304CrossRefPubMed

Becker C, Wirtz S, Blessing M et al (2003) Constitutive p40 promoter activation and IL-23 production in the terminal ileum mediated by dendritic cells. J Clin Invest 112:693–706. https://doi.org/10.1172/JCI17464CrossRefPubMedPubMedCentral

Benjamin JL, Hedin CR, Koutsoumpas A et al (2012) Smokers with active Crohn’s disease have a clinically relevant dysbiosis of the gastrointestinal microbiota. Inflamm Bowel Dis 18:1092–1100. https://doi.org/10.1002/ibd.21864CrossRefPubMed

Bennett CL, Christie J, Ramsdell F et al (2001) The immune dysregulation, polyendocrinopathy, enteropathy, X-linked syndrome (IPEX) is caused by mutations of FOXP3. Nat Genet 27:20–21. https://doi.org/10.1038/83713CrossRefPubMed

Biancheri P, Powell N, Monteleone G et al (2013) The challenges of stratifying patients for trials in inflammatory bowel disease. Trends Immunol 34:564–571. https://doi.org/10.1016/j.it.2013.08.002CrossRefPubMed

Bischoff SC, Barbara G, Buurman W et al (2014) Intestinal permeability – a new target for disease prevention and therapy. BMC Gastroenterol 14:189. https://doi.org/10.1186/s12876-014-0189-7

Botstein D, Risch N (2003) Discovering genotypes underlying human phenotypes: past successes for mendelian disease, future approaches for complex disease. Nat Genet 33(Suppl):228–237. https://doi.org/10.1038/ng1090CrossRefPubMed

Boyapati RK, Rossi AG, Satsangi J et al (2016) Gut mucosal DAMPs in IBD: from mechanisms to therapeutic implications. Mucosal Immunol 9:567–582. https://doi.org/10.1038/mi.2016.14CrossRefPubMed

Cadwell K, Liu JY, Brown SL et al (2008) A key role for autophagy and the autophagy gene Atg16l1 in mouse and human intestinal Paneth cells. Nature 456:259–263. https://doi.org/10.1038/nature07416CrossRefPubMedPubMedCentral

Cadwell K, Patel KK, Maloney NS et al (2010) Virus-plus-susceptibility gene interaction determines Crohn’s disease gene Atg16L1 phenotypes in intestine. Cell 141:1135–1145. https://doi.org/10.1016/j.cell.2010.05.009CrossRefPubMedPubMedCentral

Callaway TR, Edrington TS, Anderson RC et al (2008) Probiotics, prebiotics and competitive exclusion for prophylaxis against bacterial disease. Anim Health Res Rev 9:217–225. https://doi.org/10.1017/S1466252308001540CrossRefPubMed

Candore G, Cigna D, Todaro M et al (1995) T-cell activation in HLA-B8, DR3-positive individuals. Early antigen expression defect in vitro. Hum Immunol 42:289–294CrossRefPubMed

Cario E (2013) Microbiota and innate immunity in intestinal inflammation and neoplasia. Curr Opin Gastroenterol 29:85–91. https://doi.org/10.1097/MOG.0b013e32835a670eCrossRefPubMed

Cerutti A, Rescigno M (2008) The biology of intestinal immunoglobulin A responses. Immunity 28:740–750. https://doi.org/10.1016/j.immuni.2008.05.001CrossRefPubMedPubMedCentral

Chen G, Ran X, Li B et al (2018) Sodium butyrate inhibits inflammation and maintains epithelium barrier integrity in a TNBS-induced inflammatory bowel disease mice model. EBioMedicine 30:317–325. https://doi.org/10.1016/j.ebiom.2018.03.030CrossRefPubMedPubMedCentral

Cho JH, Gregersen PK (2011) Genomics and the multifactorial nature of human autoimmune disease. N Engl J Med 365:1612–1623. https://doi.org/10.1056/NEJMra1100030CrossRefPubMed

Claesson MJ, Cusack S, O’Sullivan O et al (2011) Composition, variability, and temporal stability of the intestinal microbiota of the elderly. Proc Natl Acad Sci USA 108(Suppl 1):4586–4591. https://doi.org/10.1073/pnas.1000097107CrossRefPubMed

Consortium UIG, Barrett JC, Lee JC et al (2009) Genome-wide association study of ulcerative colitis identifies three new susceptibility loci, including the HNF4A region. Nat Genet 41:1330–1334. https://doi.org/10.1038/ng.483CrossRef

Coombes JL, Robinson NJ, Maloy KJ et al (2005) Regulatory T cells and intestinal homeostasis. Immunol Rev 204:184–194. https://doi.org/10.1111/j.0105-2896.2005.00250.xCrossRefPubMed

Coombes JL, Siddiqui KR, Arancibia-Carcamo CV et al (2007) A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 204:1757–1764. https://doi.org/10.1084/jem.20070590CrossRefPubMedPubMedCentral

Costello S, Waters O, Bryant R et al (2017) OP36: short duration, low intensity pooled faecal microbiota transplantation induces remission in patients with mild-moderately active ulcerative colitis: a randomized controlled trial. JCC 11:S1–S23

Cuthbert AP, Fisher SA, Mirza MM et al (2002) The contribution of NOD2 gene mutations to the risk and site of disease in inflammatory bowel disease. Gastroenterology 122:867–874CrossRefPubMed

Dambacher J, Beigel F, Zitzmann K et al (2009) The role of the novel Th17 cytokine IL-26 in intestinal inflammation. Gut 58:1207–1217. https://doi.org/10.1136/gut.2007.130112CrossRefPubMed

Danese S, Rudzinski J, Brandt W et al (2015) Tralokinumab for moderate-to-severe UC: a randomised, double-blind, placebo-controlled, phase IIa study. Gut 64:243–249. https://doi.org/10.1136/gutjnl-2014-308004CrossRefPubMed

Dardalhon V, Awasthi A, Kwon H et al (2008) IL-4 inhibits TGF-beta-induced Foxp3+ T cells and together with TGF-beta, generates IL-9+ IL-10+ Foxp3(−) effector T cells. Nat Immunol 9:1347–1355. https://doi.org/10.1038/ni.1677CrossRefPubMedPubMedCentral

Darfeuille-Michaud A, Boudeau J, Bulois P et al (2004) High prevalence of adherent-invasive Escherichia coli associated with ileal mucosa in Crohn’s disease. Gastroenterology 127:412–421CrossRefPubMed

Das P, Goswami P, Das TK et al (2012) Comparative tight junction protein expressions in colonic Crohn’s disease, ulcerative colitis, and tuberculosis: a new perspective. Virchows Arch 460:261–270. https://doi.org/10.1007/s00428-012-1195-1CrossRefPubMed

Dave M, Higgins PD, Middha S et al (2012) The human gut microbiome: current knowledge, challenges, and future directions. Transl Res 160:246–257. https://doi.org/10.1016/j.trsl.2012.05.003CrossRefPubMed

de Duve C (2005) The lysosome turns fifty. Nat Cell Biol 7:847–849. https://doi.org/10.1038/ncb0905-847CrossRefPubMed

De Duve C, Pressman BC, Gianetto R et al (1955) Tissue fractionation studies. 6. Intracellular distribution patterns of enzymes in rat-liver tissue. Biochem J 60:604–617CrossRefPubMedCentral

de Vries AB, Janse M, Blokzijl H et al (2015) Distinctive inflammatory bowel disease phenotype in primary sclerosing cholangitis. World J Gastroenterol 21:1956–1971. https://doi.org/10.3748/wjg.v21.i6.1956CrossRefPubMedPubMedCentral

Dominguez-Bello MG, Blaser MJ, Ley RE et al (2011) Development of the human gastrointestinal microbiota and insights from high-throughput sequencing. Gastroenterology 140:1713–1719. https://doi.org/10.1053/j.gastro.2011.02.011CrossRefPubMed

Egea E, Iglesias A, Salazar M et al (1991) The cellular basis for lack of antibody response to hepatitis B vaccine in humans. J Exp Med 173:531–538CrossRefPubMed

Eisenhoffer GT, Loftus PD, Yoshigi M et al (2012) Crowding induces live cell extrusion to maintain homeostatic cell numbers in epithelia. Nature 484:546–549. https://doi.org/10.1038/nature10999CrossRefPubMedPubMedCentral

Ellinghaus D, Jostins L, Spain SL et al (2016) Analysis of five chronic inflammatory diseases identifies 27 new associations and highlights disease-specific patterns at shared loci. Nat Genet 48:510–518. https://doi.org/10.1038/ng.3528CrossRefPubMedPubMedCentral

Fais S, Capobianchi MR, Pallone F et al (1991) Spontaneous release of interferon gamma by intestinal lamina propria lymphocytes in Crohn’s disease. Kinetics of in vitro response to interferon gamma inducers. Gut 32:403–407CrossRefPubMedPubMedCentral

Franceschi C, Olivieri F, Marchegiani F et al (2005) Genes involved in immune response/inflammation, IGF1/insulin pathway and response to oxidative stress play a major role in the genetics of human longevity: the lesson of centenarians. Mech Ageing Dev 126:351–361. https://doi.org/10.1016/j.mad.2004.08.028CrossRefPubMed

Frank DN, Robertson CE, Hamm CM et al (2011) Disease phenotype and genotype are associated with shifts in intestinal-associated microbiota in inflammatory bowel diseases. Inflamm Bowel Dis 17:179–184. https://doi.org/10.1002/ibd.21339CrossRefPubMed

Fuchs A, Vermi et al (2013) Immunity 38:769–81

Fuss IJ, Neurath M, Boirivant M et al (1996) Disparate CD4+ lamina propria (LP) lymphokine secretion profiles in inflammatory bowel disease. Crohn’s disease LP cells manifest increased secretion of IFN-gamma, whereas ulcerative colitis LP cells manifest increased secretion of IL-5. J Immunol 157:1261–1270PubMed

Gassler N, Rohr C, Schneider A et al (2001) Inflammatory bowel disease is associated with changes of enterocytic junctions. Am J Physiol Gastrointest Liver Physiol 281:G216–G228. https://doi.org/10.1152/ajpgi.2001.281.1.G216CrossRefPubMed

Geremia A et al (2011) J Exp Med 208:1127–33

Geremia A, Arancibia-Carcamo CV (2017) Innate lymphoid cells in intestinal inflammation. Front Immunol 8:1296. https://doi.org/10.3389/fimmu.2017.01296CrossRefPubMedPubMedCentral

Geremia A, Biancheri P, Allan P et al (2014) Innate and adaptive immunity in inflammatory bowel disease. Autoimmun Rev 13:3–10. https://doi.org/10.1016/j.autrev.2013.06.004CrossRefPubMed

Glauben R, Siegmund B (2011) Inhibition of histone deacetylases in inflammatory bowel diseases. Mol Med 17:426–433. https://doi.org/10.2119/molmed.2011.00069CrossRefPubMedPubMedCentral

Glauben R, Batra A, Fedke I et al (2006) Histone hyperacetylation is associated with amelioration of experimental colitis in mice. J Immunol 176:5015–5022CrossRefPubMed

Glocker EO, Kotlarz D, Boztug K et al (2009) Inflammatory bowel disease and mutations affecting the interleukin-10 receptor. N Engl J Med 361:2033–2045. https://doi.org/10.1056/NEJMoa0907206CrossRefPubMedPubMedCentral

Goswami P, Das P, Verma AK et al (2014) Are alterations of tight junctions at molecular and ultrastructural level different in duodenal biopsies of patients with celiac disease and Crohn’s disease? Virchows Arch 465:521–530. https://doi.org/10.1007/s00428-014-1651-1CrossRefPubMed

Hampe J, Franke A, Rosenstiel P et al (2007) A genome-wide association scan of nonsynonymous SNPs identifies a susceptibility variant for Crohn disease in ATG16L1. Nat Genet 39:207–211. https://doi.org/10.1038/ng1954CrossRefPubMed

Hegazy AN, West NR, Stubbington MJT et al (2017) Circulating and tissue-resident CD4(+) T cells with reactivity to intestinal microbiota are abundant in healthy individuals and function is altered during inflammation. Gastroenterology 153:1320–1337, e1316. https://doi.org/10.1053/j.gastro.2017.07.047CrossRefPubMed

Heller F, Fuss IJ, Nieuwenhuis EE et al (2002) Oxazolone colitis, a Th2 colitis model resembling ulcerative colitis, is mediated by IL-13-producing NK-T cells. Immunity 17:629–638CrossRefPubMed

Heller F, Florian P, Bojarski C et al (2005) Interleukin-13 is the key effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and cell restitution. Gastroenterology 129:550–564. https://doi.org/10.1016/j.gastro.2005.05.002CrossRefPubMed

Heller F, Fromm A, Gitter AH et al (2008) Epithelial apoptosis is a prominent feature of the epithelial barrier disturbance in intestinal inflammation: effect of pro-inflammatory interleukin-13 on epithelial cell function. Mucosal Immunol 1(Suppl 1):S58–S61. https://doi.org/10.1038/mi.2008.46CrossRefPubMed

Hofmann C, Dunger N, Doser K et al (2014) Physiologic TLR9-CpG-DNA interaction is essential for the homeostasis of the intestinal immune system. Inflamm Bowel Dis 20:136–143. https://doi.org/10.1097/01.MIB.0000436276.19755.c1CrossRefPubMed

Huber S, Gagliani N, Esplugues E et al (2011) Th17 cells express interleukin-10 receptor and are controlled by Foxp3(−) and Foxp3+ regulatory CD4+ T cells in an interleukin-10-dependent manner. Immunity 34:554–565. https://doi.org/10.1016/j.immuni.2011.01.020CrossRefPubMedPubMedCentral

Hueber W, Sands BE, Lewitzky S et al (2012) Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn’s disease: unexpected results of a randomised, double-blind placebo-controlled trial. Gut 61:1693–1700. https://doi.org/10.1136/gutjnl-2011-301668CrossRefPubMed

Hugot JP, Chamaillard M, Zouali H et al (2001) Association of NOD2 leucine-rich repeat variants with susceptibility to Crohn’s disease. Nature 411:599–603. https://doi.org/10.1038/35079107CrossRefPubMed

Ivanov II, Atarashi K, Manel N et al (2009) Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell 139:485–498. https://doi.org/10.1016/j.cell.2009.09.033CrossRefPubMedPubMedCentral

Johansson ME, Larsson JM, Hansson GC (2011) The two mucus layers of colon are organized by the MUC2 mucin, whereas the outer layer is a legislator of host-microbial interactions. Proc Natl Acad Sci USA 108(Suppl 1):4659–4665. https://doi.org/10.1073/pnas.1006451107CrossRefPubMed

Johansson-Lindbom B, Svensson M, Pabst O et al (2005) Functional specialization of gut CD103+ dendritic cells in the regulation of tissue-selective T cell homing. J Exp Med 202:1063–1073. https://doi.org/10.1084/jem.20051100CrossRefPubMedPubMedCentral

Jostins L, Ripke S, Weersma RK et al (2012) Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. Nature 491:119–124. https://doi.org/10.1038/nature11582CrossRefPubMedPubMedCentral

Kamada N, Chen G, Nunez G (2012) A complex microworld in the gut: harnessing pathogen-commensal relations. Nat Med 18:1190–1191. https://doi.org/10.1038/nm.2900CrossRefPubMed

Kang S, Denman SE, Morrison M et al (2010) Dysbiosis of fecal microbiota in Crohn’s disease patients as revealed by a custom phylogenetic microarray. Inflamm Bowel Dis 16:2034–2042. https://doi.org/10.1002/ibd.21319CrossRefPubMed

Klag T, Stange EF, Wehkamp J (2013) Defective antibacterial barrier in inflammatory bowel disease. Dig Dis 31:310–316. https://doi.org/10.1159/000354858CrossRefPubMed

Krug SM, Schulzke JD, Fromm M (2014) Tight junction, selective permeability, and related diseases. Semin Cell Dev Biol 36:166–176. https://doi.org/10.1016/j.semcdb.2014.09.002CrossRefPubMed

Kucharzik T, Walsh SV, Chen J et al (2001) Neutrophil transmigration in inflammatory bowel disease is associated with differential expression of epithelial intercellular junction proteins. Am J Pathol 159:2001–2009. https://doi.org/10.1016/S0002-9440(10)63051-9CrossRefPubMedPubMedCentral

Kuhn R, Lohler J, Rennick D et al (1993) Interleukin-10-deficient mice develop chronic enterocolitis. Cell 75:263–274CrossRefPubMed

Laserna-Mendieta EJ, Clooney AG, Carretero-Gomez JF et al (2018) Determinants of reduced genetic capacity for butyrate synthesis by the gut microbiome in Crohn’s disease and ulcerative colitis. J Crohns Colitis 12:204–216. https://doi.org/10.1093/ecco-jcc/jjx137CrossRefPubMed

Lee JH, Noh J, Noh G et al (2011) Allergen-specific transforming growth factor-beta-producing CD19+CD5+ regulatory B-cell (Br 3) responses in human late eczematous allergic reactions to cow’s milk. J Interferon Cytokine Res 31:441–449. https://doi.org/10.1089/jir.2010.0020CrossRefPubMed

Lee JC, Espeli M, Anderson CA et al (2013) Human SNP links differential outcomes in inflammatory and infectious disease to a FOXO3-regulated pathway. Cell 155:57–69. https://doi.org/10.1016/j.cell.2013.08.034CrossRefPubMedPubMedCentral

Lee JC, Biasci D, Roberts R et al (2017) Genome-wide association study identifies distinct genetic contributions to prognosis and susceptibility in Crohn’s disease. Nat Genet 49:262–268. https://doi.org/10.1038/ng.3755CrossRefPubMedPubMedCentral

Leiper K, Martin K, Ellis A et al (2011) Randomised placebo-controlled trial of rituximab (anti-CD20) in active ulcerative colitis. Gut 60:1520–1526. https://doi.org/10.1136/gut.2010.225482CrossRefPubMed

Leppkes M, Becker C, Ivanov II et al (2009) RORgamma-expressing Th17 cells induce murine chronic intestinal inflammation via redundant effects of IL-17A and IL-17F. Gastroenterology 136:257–267. https://doi.org/10.1053/j.gastro.2008.10.018CrossRefPubMed

Leung JM, Davenport M, Wolff MJ et al (2014) IL-22-producing CD4+ cells are depleted in actively inflamed colitis tissue. Mucosal Immunol 7:124–133. https://doi.org/10.1038/mi.2013.31CrossRefPubMed

Levy M, Thaiss CA, Katz MN et al (2015) Inflammasomes and the microbiota—partners in the preservation of mucosal homeostasis. Semin Immunopathol 37:39–46. https://doi.org/10.1007/s00281-014-0451-7CrossRefPubMed

Ley RE, Hamady M, Lozupone C et al (2008) Evolution of mammals and their gut microbes. Science 320:1647–1651. https://doi.org/10.1126/science.1155725CrossRefPubMedPubMedCentral

Lissner D, Schumann M, Batra A et al (2015) Monocyte and M1 macrophage-induced barrier defect contributes to chronic intestinal inflammation in IBD. Inflamm Bowel Dis 21:1297–1305. https://doi.org/10.1097/MIB.0000000000000384CrossRefPubMed

Liu JZ, van Sommeren S, Huang H et al (2015) Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations. Nat Genet 47:979–986. https://doi.org/10.1038/ng.3359CrossRefPubMedPubMedCentral

Loftus EV Jr, Harewood GC, Loftus CG et al (2005) PSC-IBD: a unique form of inflammatory bowel disease associated with primary sclerosing cholangitis. Gut 54:91–96. https://doi.org/10.1136/gut.2004.046615CrossRefPubMedPubMedCentral

Lozupone CA, Stombaugh JI, Gordon JI et al (2012) Diversity, stability and resilience of the human gut microbiota. Nature 489:220–230. https://doi.org/10.1038/nature11550CrossRefPubMedPubMedCentral

Lupp C, Robertson ML, Wickham ME et al (2007) Host-mediated inflammation disrupts the intestinal microbiota and promotes the overgrowth of Enterobacteriaceae. Cell Host Microbe 2:119–129. https://doi.org/10.1016/j.chom.2007.06.010CrossRefPubMed

Manichanh C, Rigottier-Gois L, Bonnaud E et al (2006) Reduced diversity of faecal microbiota in Crohn’s disease revealed by a metagenomic approach. Gut 55:205–211. https://doi.org/10.1136/gut.2005.073817CrossRefPubMedPubMedCentral

Martin-de-Carpi J, Rodriguez A, Ramos E et al (2013) Increasing incidence of pediatric inflammatory bowel disease in Spain (1996–2009): the SPIRIT Registry. Inflamm Bowel Dis 19:73–80. https://doi.org/10.1002/ibd.22980CrossRefPubMed

Martinez C, Antolin M, Santos J et al (2008) Unstable composition of the fecal microbiota in ulcerative colitis during clinical remission. Am J Gastroenterol 103:643–648. https://doi.org/10.1111/j.1572-0241.2007.01592.xCrossRefPubMed

Mattner J, Schmidt F, Siegmund B (2016) Faecal microbiota transplantation—a clinical view. Int J Med Microbiol 306:310–315. https://doi.org/10.1016/j.ijmm.2016.02.003CrossRefPubMed

McGovern DP, Jones MR, Taylor KD et al (2010) Fucosyltransferase 2 (FUT2) non-secretor status is associated with Crohn’s disease. Hum Mol Genet 19:3468–3476. https://doi.org/10.1093/hmg/ddq248CrossRefPubMedPubMedCentral

McGovern DP, Kugathasan S, Cho JH (2015) Genetics of inflammatory bowel diseases. Gastroenterology 149:1163–1176, e1162. https://doi.org/10.1053/j.gastro.2015.08.001CrossRefPubMed

Moayyedi P, Surette MG, Kim PT et al (2015) Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial. Gastroenterology 149:102–109, e106. https://doi.org/10.1053/j.gastro.2015.04.001CrossRefPubMed

Modica MA, Cammarata G, Caruso C (1990) HLA-B8, DR3 phenotype and lymphocyte responses to phytohaemagglutinin. J Immunogenet 17:101–107CrossRefPubMed

Mokry M, Middendorp S, Wiegerinck CL et al (2014) Many inflammatory bowel disease risk loci include regions that regulate gene expression in immune cells and the intestinal epithelium. Gastroenterology 146:1040–1047. https://doi.org/10.1053/j.gastro.2013.12.003CrossRefPubMed

Monteleone G, Monteleone I, Fina D et al (2005) Interleukin-21 enhances T-helper cell type I signaling and interferon-gamma production in Crohn’s disease. Gastroenterology 128:687–694CrossRefPubMed

Morgan XC, Tickle TL, Sokol H et al (2012) Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol 13:R79. https://doi.org/10.1186/gb-2012-13-9-r79CrossRefPubMedPubMedCentral

Muise AM, Walters TD, Glowacka WK et al (2009) Polymorphisms in E-cadherin (CDH1) result in a mis-localised cytoplasmic protein that is associated with Crohn’s disease. Gut 58:1121–1127. https://doi.org/10.1136/gut.2008.175117CrossRefPubMed

Nalleweg N, Chiriac MT, Podstawa E et al (2015) IL-9 and its receptor are predominantly involved in the pathogenesis of UC. Gut 64:743–755. https://doi.org/10.1136/gutjnl-2013-305947CrossRefPubMed

Neurath MF, Weigmann B, Finotto S et al (2002) The transcription factor T-bet regulates mucosal T cell activation in experimental colitis and Crohn’s disease. J Exp Med 195:1129–1143CrossRefPubMedPubMedCentral

Ning K, Gettler K, Zhang W et al (2015) Improved integrative framework combining association data with gene expression features to prioritize Crohn’s disease genes. Hum Mol Genet 24:4147–4157. https://doi.org/10.1093/hmg/ddv142CrossRefPubMedPubMedCentral

O’Connor W Jr, Kamanaka M, Booth CJ et al (2009) A protective function for interleukin 17A in T cell-mediated intestinal inflammation. Nat Immunol 10:603–609. https://doi.org/10.1038/ni.1736CrossRefPubMedPubMedCentral

O’Hara AM, Shanahan F (2006) The gut flora as a forgotten organ. EMBO Rep 7:688–693. https://doi.org/10.1038/sj.embor.7400731CrossRefPubMedPubMedCentral

Ohkusa T, Sato N, Ogihara T et al (2002) Fusobacterium varium localized in the colonic mucosa of patients with ulcerative colitis stimulates species-specific antibody. J Gastroenterol Hepatol 17:849–853CrossRefPubMed

Oshima T, Miwa H, Joh T (2008) Changes in the expression of claudins in active ulcerative colitis. J Gastroenterol Hepatol 23(Suppl 2):S146–S150. https://doi.org/10.1111/j.1440-1746.2008.05405.xCrossRefPubMed

Ott SJ, Kuhbacher T, Musfeldt M et al (2008) Fungi and inflammatory bowel diseases: alterations of composition and diversity. Scand J Gastroenterol 43:831–841. https://doi.org/10.1080/00365520801935434CrossRefPubMed

Ott SJ, Waetzig GH, Rehman A et al (2017) Efficacy of sterile fecal filtrate transfer for treating patients with clostridium difficile infection. Gastroenterology 152:799–811, e797. https://doi.org/10.1053/j.gastro.2016.11.010CrossRefPubMed

Pabst O (2012) New concepts in the generation and functions of IgA. Nat Rev Immunol 12:821–832. https://doi.org/10.1038/nri3322CrossRefPubMed

Padyukov L, Seielstad M, Ong RT et al (2011) A genome-wide association study suggests contrasting associations in ACPA-positive versus ACPA-negative rheumatoid arthritis. Ann Rheum Dis 70:259–265. https://doi.org/10.1136/ard.2009.126821CrossRefPubMed

Paramsothy S, Kamm MA, Kaakoush NO et al (2017) Multidonor intensive faecal microbiota transplantation for active ulcerative colitis: a randomised placebo-controlled trial. Lancet 389:1218–1228. https://doi.org/10.1016/S0140-6736(17)30182-4CrossRefPubMed

Parkes M, Barrett JC, Prescott NJ et al (2007) Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn’s disease susceptibility. Nat Genet 39:830–832. https://doi.org/10.1038/ng2061CrossRefPubMedPubMedCentral

Parrello T, Monteleone G, Cucchiara S et al (2000) Up-regulation of the IL-12 receptor beta 2 chain in Crohn’s disease. J Immunol 165:7234–7239CrossRefPubMed

Pearson AD, Eastham EJ, Laker MF et al (1982) Intestinal permeability in children with Crohn’s disease and coeliac disease. Br Med J (Clin Res Ed) 285:20–21CrossRef

Pickert G, Neufert C, Leppkes M et al (2009) STAT3 links IL-22 signaling in intestinal epithelial cells to mucosal wound healing. J Exp Med 206:1465–1472. https://doi.org/10.1084/jem.20082683CrossRefPubMedPubMedCentral

Raine T, Liu JZ, Anderson CA et al (2015) Generation of primary human intestinal T cell transcriptomes reveals differential expression at genetic risk loci for immune-mediated disease. Gut 64:250–259. https://doi.org/10.1136/gutjnl-2013-306657CrossRefPubMed

Reinisch W, Hommes DW, Van Assche G et al (2006) A dose escalating, placebo controlled, double blind, single dose and multidose, safety and tolerability study of fontolizumab, a humanised anti-interferon gamma antibody, in patients with moderate to severe Crohn’s disease. Gut 55:1138–1144. https://doi.org/10.1136/gut.2005.079434CrossRefPubMedPubMedCentral

Rioux JD, Xavier RJ, Taylor KD et al (2007) Genome-wide association study identifies new susceptibility loci for Crohn disease and implicates autophagy in disease pathogenesis. Nat Genet 39:596–604. https://doi.org/10.1038/ng2032CrossRefPubMedPubMedCentral

Rossen NG, Fuentes S, van der Spek MJ et al (2015) Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis. Gastroenterology 149:110–118, e114. https://doi.org/10.1053/j.gastro.2015.03.045CrossRefPubMed

Rubinstein MR, Wang X, Liu W et al (2013) Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating E-cadherin/beta-catenin signaling via its FadA adhesin. Cell Host Microbe 14:195–206. https://doi.org/10.1016/j.chom.2013.07.012CrossRefPubMedPubMedCentral

Saitoh T, Fujita N, Jang MH et al (2008) Loss of the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456:264–268. https://doi.org/10.1038/nature07383CrossRefPubMed

Sakuraba A, Sato T, Kamada N et al (2009) Th1/Th17 immune response is induced by mesenteric lymph node dendritic cells in Crohn’s disease. Gastroenterology 137:1736–1745. https://doi.org/10.1053/j.gastro.2009.07.049CrossRefPubMed

Salim SY, Soderholm JD (2011) Importance of disrupted intestinal barrier in inflammatory bowel diseases. Inflamm Bowel Dis 17:362–381. https://doi.org/10.1002/ibd.21403CrossRefPubMed

Sarra M, Monteleone I, Stolfi C et al (2010) Interferon-gamma-expressing cells are a major source of interleukin-21 in inflammatory bowel diseases. Inflamm Bowel Dis 16:1332–1339. https://doi.org/10.1002/ibd.21238CrossRefPubMed

Sartor RB (2008) Microbial influences in inflammatory bowel diseases. Gastroenterology 134:577–594. https://doi.org/10.1053/j.gastro.2007.11.059CrossRefPubMed

Satsangi J, Grootscholten C, Holt H et al (1996) Clinical patterns of familial inflammatory bowel disease. Gut 38:738–741CrossRefPubMedPubMedCentral

Schmitt E, Beuscher HU, Huels C et al (1991) IL-1 serves as a secondary signal for IL-9 expression. J Immunol 147:3848–3854PubMed

Schmitt E, Germann T, Goedert S et al (1994) IL-9 production of naive CD4+ T cells depends on IL-2, is synergistically enhanced by a combination of TGF-beta and IL-4, and is inhibited by IFN-gamma. J Immunol 153:3989–3996PubMed

Schwerd T, Frivolt K, Clavel T et al (2016) Exclusive enteral nutrition in active pediatric Crohn disease: effects on intestinal microbiota and immune regulation. J Allergy Clin Immunol 138:592–596. https://doi.org/10.1016/j.jaci.2015.12.1331CrossRefPubMed

Siegmund B (2010) Interleukin-18 in intestinal inflammation: friend and foe? Immunity 32:300–302. https://doi.org/10.1016/j.immuni.2010.03.010CrossRefPubMed

Siegmund B, Lehr HA, Fantuzzi G et al (2001) IL-1 beta -converting enzyme (caspase-1) in intestinal inflammation. Proc Natl Acad Sci USA 98:13249–13254. https://doi.org/10.1073/pnas.231473998CrossRefPubMedPubMedCentral

Simpson SJ, Shah S, Comiskey M et al (1998) T cell-mediated pathology in two models of experimental colitis depends predominantly on the interleukin 12/Signal transducer and activator of transcription (Stat)-4 pathway, but is not conditional on interferon gamma expression by T cells. J Exp Med 187:1225–1234CrossRefPubMedPubMedCentral

Smith PD, Smythies LE, Shen R et al (2011) Intestinal macrophages and response to microbial encroachment. Mucosal Immunol 4:31–42. https://doi.org/10.1038/mi.2010.66CrossRefPubMed

Spits H, Artis D, Colonna M et al (2013) Innate lymphoid cells – a proposal for uniform nomenclature. Nat Rev Immunol 13:145–149. https://doi.org/10.1038/nri3365

Stroh T, Batra A, Glauben R et al (2008) Nucleotide oligomerization domains 1 and 2: regulation of expression and function in preadipocytes. J Immunol 181:3620–3627CrossRefPubMed

Swidsinski A, Ladhoff A, Pernthaler A et al (2002) Mucosal flora in inflammatory bowel disease. Gastroenterology 122:44–54CrossRefPubMed

Swidsinski A, Loening-Baucke V, Theissig F et al (2007) Comparative study of the intestinal mucus barrier in normal and inflamed colon. Gut 56:343–350. https://doi.org/10.1136/gut.2006.098160CrossRefPubMed

Szebeni B, Veres G, Dezsofi A et al (2008) Increased expression of Toll-like receptor (TLR) 2 and TLR4 in the colonic mucosa of children with inflammatory bowel disease. Clin Exp Immunol 151:34–41. https://doi.org/10.1111/j.1365-2249.2007.03531.xCrossRefPubMedPubMedCentral

te Velde AA, van Kooyk Y, Braat H et al (2003) Increased expression of DC-SIGN+IL-12+IL-18+ and CD83+IL-12-IL-18- dendritic cell populations in the colonic mucosa of patients with Crohn’s disease. Eur J Immunol 33:143–151. https://doi.org/10.1002/immu.200390017CrossRef

Testro AG, Visvanathan K (2009) Toll-like receptors and their role in gastrointestinal disease. J Gastroenterol Hepatol 24:943–954. https://doi.org/10.1111/j.1440-1746.2009.05854.xCrossRefPubMed

Thuijls G, Derikx JP, de Haan JJ et al (2010) Urine-based detection of intestinal tight junction loss. J Clin Gastroenterol 44:e14–e19. https://doi.org/10.1097/MCG.0b013e31819f5652CrossRefPubMed

Turnbaugh PJ, Hamady M, Yatsunenko T et al (2009) A core gut microbiome in obese and lean twins. Nature 457:480–484. https://doi.org/10.1038/nature07540CrossRefPubMed

Turner JR (2009) Intestinal mucosal barrier function in health and disease. Nat Rev Immunol 9:799–809. https://doi.org/10.1038/nri2653CrossRefPubMed

Uhlig HH, Muise AM (2017) Clinical genomics in inflammatory bowel disease. Trends Genet 33:629–641. https://doi.org/10.1016/j.tig.2017.06.008CrossRefPubMed

Uhlig HH, Schwerd T, Koletzko S et al (2014) The diagnostic approach to monogenic very early onset inflammatory bowel disease. Gastroenterology 147:990–1007, e1003. https://doi.org/10.1053/j.gastro.2014.07.023CrossRefPubMed

Uyttenhove C, Brombacher F, Van Snick J (2010) TGF-beta interactions with IL-1 family members trigger IL-4-independent IL-9 production by mouse CD4(+) T cells. Eur J Immunol 40:2230–2235. https://doi.org/10.1002/eji.200940281CrossRefPubMed

Van der Sluis M, De Koning BA, De Bruijn AC et al (2006) Muc2-deficient mice spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. Gastroenterology 131:117–129. https://doi.org/10.1053/j.gastro.2006.04.020CrossRefPubMed

van Heel DA, Ghosh S, Butler M et al (2005) Muramyl dipeptide and toll-like receptor sensitivity in NOD2-associated Crohn’s disease. Lancet 365:1794–1796. https://doi.org/10.1016/S0140-6736(05)66582-8CrossRefPubMed

van Nood E, Vrieze A, Nieuwdorp M et al (2013) Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med 368:407–415. https://doi.org/10.1056/NEJMoa1205037CrossRefPubMed

Voedisch S, Koenecke C, David S et al (2009) Mesenteric lymph nodes confine dendritic cell-mediated dissemination of Salmonella enterica serovar Typhimurium and limit systemic disease in mice. Infect Immun 77:3170–3180. https://doi.org/10.1128/IAI.00272-09CrossRefPubMedPubMedCentral

Wallace KL, Zheng LB, Kanazawa Y et al (2014) Immunopathology of inflammatory bowel disease. World J Gastroenterol 20:6–21. https://doi.org/10.3748/wjg.v20.i1.6CrossRefPubMedPubMedCentral

Watanabe T, Kitani A, Murray PJ et al (2004) NOD2 is a negative regulator of Toll-like receptor 2-mediated T helper type 1 responses. Nat Immunol 5:800–808. https://doi.org/10.1038/ni1092CrossRefPubMed

Wehkamp J, Harder J, Weichenthal M et al (2003) Inducible and constitutive beta-defensins are differentially expressed in Crohn’s disease and ulcerative colitis. Inflamm Bowel Dis 9:215–223CrossRefPubMed

Wehkamp J, Harder J, Weichenthal M et al (2004) NOD2 (CARD15) mutations in Crohn’s disease are associated with diminished mucosal alpha-defensin expression. Gut 53:1658–1664. https://doi.org/10.1136/gut.2003.032805CrossRefPubMedPubMedCentral

Wehkamp J, Salzman NH, Porter E et al (2005) Reduced paneth cell alpha-defensins in ileal Crohn’s disease. Proc Natl Acad Sci USA 102:18129–18134. https://doi.org/10.1073/pnas.0505256102CrossRefPubMedPubMedCentral

Wehkamp J, Wang G, Kubler I et al (2007) The Paneth cell alpha-defensin deficiency of ileal Crohn’s disease is linked to Wnt/Tcf-4. J Immunol 179:3109–3118CrossRefPubMed

Wellcome Trust Case Control C (2007) Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature 447:661–678. https://doi.org/10.1038/nature05911CrossRef

Willing B, Halfvarson J, Dicksved J et al (2009) Twin studies reveal specific imbalances in the mucosa-associated microbiota of patients with ileal Crohn’s disease. Inflamm Bowel Dis 15:653–660. https://doi.org/10.1002/ibd.20783CrossRefPubMed

Wirtz S, Finotto S, Kanzler S et al (1999) Cutting edge: chronic intestinal inflammation in STAT-4 transgenic mice: characterization of disease and adoptive transfer by TNF- plus IFN-gamma-producing CD4+ T cells that respond to bacterial antigens. J Immunol 162:1884–1888PubMed

Yuan A, Yang H, Qi H et al (2015) IL-9 antibody injection suppresses the inflammation in colitis mice. Biochem Biophys Res Commun 468:921–926. https://doi.org/10.1016/j.bbrc.2015.11.057CrossRefPubMed

Zaki MH, Boyd KL, Vogel P et al (2010) The NLRP3 inflammasome protects against loss of epithelial integrity and mortality during experimental colitis. Immunity 32:379–391. https://doi.org/10.1016/j.immuni.2010.03.003CrossRefPubMedPubMedCentral

Zasloff M (2002) Antimicrobial peptides of multicellular organisms. Nature 415:389–395. https://doi.org/10.1038/415389aCrossRefPubMed

Zeissig S, Burgel N, Gunzel D et al (2007) Changes in expression and distribution of claudin 2, 5 and 8 lead to discontinuous tight junctions and barrier dysfunction in active Crohn’s disease. Gut 56:61–72. https://doi.org/10.1136/gut.2006.094375CrossRefPubMed

Zenewicz LA, Yancopoulos GD, Valenzuela DM et al (2008) Innate and adaptive interleukin-22 protects mice from inflammatory bowel disease. Immunity 29:947–957. https://doi.org/10.1016/j.immuni.2008.11.003CrossRefPubMedPubMedCentral

Zhong Y, Kinio A, Saleh M (2013) Functions of NOD-like receptors in human diseases. Front Immunol 4:333. https://doi.org/10.3389/fimmu.2013.00333CrossRefPubMedPubMedCentral

Zhou L, Zhang M, Wang Y et al (2018) Faecalibacterium prausnitzii produces butyrate to maintain Th17/Treg balance and to ameliorate colorectal colitis by inhibiting histone deacetylase 1. Inflamm Bowel Dis. https://doi.org/10.1093/ibd/izy182CrossRefPubMedPubMedCentral

Zigmond E, Varol C, Farache J et al (2012) Ly6C hi monocytes in the inflamed colon give rise to proinflammatory effector cells and migratory antigen-presenting cells. Immunity 37:1076–1090. https://doi.org/10.1016/j.immuni.2012.08.026CrossRefPubMed

Zimmermann J, Durek P, Kuhl AA et al (2018) The intestinal microbiota determines the colitis-inducing potential of T-bet-deficient Th cells in mice. Eur J Immunol 48:161–167. https://doi.org/10.1002/eji.201747100CrossRefPubMed

Titel: Pathogenese chronisch-entzündlicher Darmerkrankungen
verfasst von: Britta Siegmund
Verlag: Springer Berlin Heidelberg
Buch: Chronisch-entzündliche Darmerkrankungen
Print ISBN: 978-3-662-59103-1

Electronic ISBN: 978-3-662-59104-8

Copyright-Jahr: 2020
DOI: https://doi.org/10.1007/978-3-662-59104-8_3

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

^{Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag}

Kostenlos registrieren

Neu im Fachgebiet Innere Medizin

NSCLC: Progressionsfreies Überleben unter Osimertinib fast versiebenfacht

06.06.2024 ASCO 2024 Kongressbericht

Erste Ergebnisse der Phase-III-Studie LAURA etablieren Osimertinib als neuen Therapiestandard für Menschen mit nicht-resezierbarem, EGFR-mutiertem, nicht-kleinzelligem Lungenkarzinom im Stadium III, die nach definitiver Radiochemotherapie progressionsfrei sind. Auf der ASCO-Tagung wurden diese beeindruckenden Ergebnisse besprochen.

Hodgkin Lymphom: BrECADD-Regime übertrifft die Erwartungen

05.06.2024 ASCO 2024 Kongressbericht

Das Kombinationsregime BrECADD mit Brentuximab vedotin ermöglichte in der Studie HD21 beim fortgeschrittenen klassischen Hodgkin-Lymphom eine unerwartet hohe progressionsfreie Überlebensrate von 94,3% nach vier Jahren. Gleichzeitig war das Regime besser tolerabel als der bisherige Standard eBEACOPP.

Antikörper-Drug-Konjugat verdoppelt PFS bei Multiplem Myelom

05.06.2024 ASCO 2024 Nachrichten

Zwei Phase-3-Studien deuten auf erhebliche Vorteile des Antikörper-Wirkstoff-Konjugats Belantamab-Mafodotin bei vorbehandelten Personen mit Multiplem Myelom: Im Vergleich mit einer Standard-Tripeltherapie wurde das progressionsfreie Überleben teilweise mehr als verdoppelt.

Neuer TKI gegen CML: Höhere Wirksamkeit, seltener Nebenwirkungen

05.06.2024 Chronische myeloische Leukämie Nachrichten

Der Tyrosinkinasehemmer (TKI) Asciminib ist älteren Vertretern dieser Gruppe bei CML offenbar überlegen: Personen mit frisch diagnostizierter CML entwickelten damit in einer Phase-3-Studie häufiger eine gute molekulare Response, aber seltener ernste Nebenwirkungen.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.

Newsletter bestellen